Skip to main content
. 2013 Nov 13;39(4):919–933. doi: 10.1038/npp.2013.292

Figure 3.

Figure 3

RU-38486 prevents the CMS-induced impairment in LTP in the vSub-NAc pathway. (a) When tested on day 23, the CMS-Veh group demonstrated significantly reduced amplitude compared with all groups post HFS (*p<0.05). (b) When tested on day 23, the CMS-Veh group demonstrated significantly reduced slope compared with all the groups post HFS (*p<0.05; **p<0.01). (c) When the drugs were injected without stress exposure, the RU group demonstrated reduced amplitude compared with the Vehicle and AM groups, and the WIN group demonstrated reduced amplitude compared with the AM group (*p<0.05; **p<0.01; ***p<0.001). (d) When the drugs were injected without stress exposure, the RU group demonstrated reduced slope compared with the Vehicle and WIN groups (*p<0.05; **p<0.01).